Abstract:Objective To evaluate the pharmacokinetic parameters of a new domesticcompound glibenclamide and metformin and its relative bioavailability in healthyvolunteers. Methods A randomized, open, crossover study of 20 healthy Chinesevolunteers was conducted with a oral single dose of capsule (glibenclamide 1.25mg and metformin 250 mg per pill) 2 pills or glibenclamide 2.5 mg and metformin 500mg were given at the same time. The plasma concentrations of glibenclamide andmetformin in healthy volunteers were determined by an validated LC-MS/MS methodand were assessed with non-compartment model to obtain the pharmacokineticparameters. The relative bioavailability of compound glibenclamide and metformincapsule versus glibenclamide and metformin were calculated. Results Thepharmacokinetic parameters of glibenclamide for orally administered domesticglibenclamide capsule and glibenclamide and metformin were as following: AUC0-t :(603.32±196.61) and (581.70±195.01) ng.h.mL-1;Cmax :(123.46±27.03)and (128.28±3.67) ng.mL-1;tmax: (2.8±0.7) and (2.6±0.6) h; t1/2:(6.54±1.24)and (6.89±1.73) h. The pharmacokinetic parameters of metformin for orallyadministered domestic glibenclamide capsule and glibenclamide and metforminwere as following: AUC0-t : (7832.97±2603.38) and (7765.52±2870.85) ng. h.mL-1;Cmax: (1377.55±476.60) and (1367.40±551.19)ng.mL-1; tmax; (2.7±0.9) and (2.0±0.5) h; t1/2: (5.72±1.24) and (5.81±1.51)h, respectively. There were no significant differences(P0.05) in AUC0-t , tmax, Cmax and t1/2 between two preparations.The relative bioavailability of glibenclamide and metformin of glibenclamide casule were (104.82±19.27)% and (107.30±46.40)% compared with glibenclamide and metformin tablets. No clear adverse events were observed during this study.Conclusion glibenclamide capsule and glibenclamide and metformin tablets were bioequivalent.

Bioequivalence of Gliclazide Sustained Release Tablets

The Bioequivalence Study of Domestic and Imported Gliclazide Sustained Release Tablets

Study of the Bioequivalence of Gliclazide in Chinese Healthy Volunteers

Bioequivalence of gliclazide tablets in Chinese healthy volunteers

Bioequivalence of glipizide orally disintegrating tablets in healthy volunteers

Bioequivalence of Glipizide Controlled-Release Tablets in Chinese Healthy Volunteers

Study on bioequivalence of cilostazol table in healthy volunteers

Evaluation of the Bioequivalence and Pharmacokinetics of Two Formulations of Gliclazide in Healthy Chinese Volunteers Using Population Pharmacokinetic Approach

Bioequivalence of Repaglinide in Healthy Volunteers

Study on bioequivalence of domestic and imported glipizide tablets

Study of bioequivalence of compound metformin hydrochloride tablet in healthy volunteers

Bioequivalence of Rosiglitazone in Healthy Volunteers

Study on the Relative Bioavailability and Bioequiavailability of Glipizide Capsule

Study on the relative bioavailability of metformin hydrochloride sustained-release tablets

Relative bioavailability of compound metformin hydrochloride tablets in healthy volunteers

Pharmacokinetics of glibenclamide/metformin hydrochloride combination

Pharmacokinetics and bioequivalance of domestic compound glibenclamide and metformin in chinese healthy volunteers

Bioequivalence of Two Domestic Praperations of Metformin Hydrochloride Entericcoated Capsules in Chinese Healthy Volunteers

Study on bioequivalence and pharmacokinetics of compound glycyrrhizin capsules in healthy volunteers

Bioequivalence of Rosiglitazone Tartrate Tables and Rosiglitazone Maleate Tables in Healthy Volunteers

Bioequivalence of glycyrrhizin capsules by HPLC-MS